• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Patients and Caregivers Aim to Raise Funds for Myeloma Research

by MM360 Staff | Aug 12, 2025 | Uncategorized

Source: CureToday articles Ashley Dieks and Dr. Saad Z. Usmani discussed how bicycling may help patients cope with the emotional and physical challenges of their myeloma diagnosis. Read More

FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma

by MM360 Staff | Aug 1, 2025 | Uncategorized

Source: CureToday articles SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for relapsed/refractory multiple myeloma. Read More

Patient Perspective: Navigating Multiple Myeloma Treatment

by MM360 Staff | Jul 30, 2025 | Uncategorized

Source: CureToday articles Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but collaborative, personalized care—including early access to cutting-edge four-drug regimens, clear communication, and...

VIDEO: Four drugs ‘appear to be better’ in treatment of newly diagnosed multiple myeloma

by Victoria Langowska | Jul 23, 2025 | Uncategorized

CHICAGO — In this video, Sham Mailankody, MBBS, highlights data from a study of carfilzomib, lenalidomide and dexamethasone, with or without daratumumab, for patients with newly diagnosed multiple myeloma.“Four drugs appear to be better than three drugs, even in the...

VIDEO: Cilta-cel may offer ‘cure’ in relapsed, refractory multiple myeloma

by Victoria Langowska | Jul 23, 2025 | Uncategorized

CHICAGO — In this video, Sham Mailankody, MBBS, discusses results from the long-term follow-up of CARTITUDE-1 patients receiving ciltacabtagene autoleucel, or cilta-cel, for the treatment of relapsed or refractory multiple myeloma.“A third of the patients were...

FDA Votes Against Proposed Blenrep Treatment Combo’s for Multiple Myeloma

by MM360 Staff | Jul 19, 2025 | Uncategorized

Source: CureToday articles The FDA’s Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple myeloma patient population. Read More
« Older Entries
Next Entries »

Recent Content

  • Oral treatment for ovarian cancer put on FDA fast track
  • J&J seeks approval in EU of Tecvayli-Darzalex for hard-to-treat myeloma
  • 1st 4 patients in AML treatment combo trial show response
  • A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
  • The efficacy and safety of CAR-T therapy in relapsed or refractory multiple myeloma patients: a systematic review and meta-analysis
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT